Sponsor Deadline
Posted: 4/18/2022

Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01, R21 Clinical Trial Optional)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention.

The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

This FOA encourages applications for well-developed research projects using the NIH R01 grant mechanism. The companion FOA, PAR-19-280 is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.


Application Due Date(s): July 15, 2019; November 15, 2019; July 15, 2020; November 15, 2020

PAR-19-279 Expiration Date November 16, 2020 

Areas of Interest

MMDPQ1: What risk factors, singularly or in cooperation, explain the variation in monoclonal gammopathy of undetermined significance (MGUS) incidence among different races?

MMDPQ2: What characteristics of immune status and response co-vary with racial/ethnic differences for MGUS incidence, and do these factors influence progression to multiple myeloma?

MMDPQ3: What are the mutational signatures of early onset vs. late onset multiple myelomas across diverse racial/ethnic patient populations?

MMDPQ4: What factors explain the difference in age-adjusted incidence rates for multiple myeloma between males and females? Do these factors play a role in earlier stages of the disease such as MGUS?

MMDPQ5: Can mouse or other preclinical models be developed that accurately reproduce characteristics of the various stages of progression from MGUS to SMM to MM?

MMDPQ6: Are there racial/ethnic differences in the natural history of and response to multiple myeloma therapies including chemotherapy, steroids, targeted therapy, immunotherapy, radiation, and stem cell therapy and, if so, what are the underlying mechanisms?